VPA response in SMA is suppressed by the fatty acid translocase CD36. - Wikidata - thesis-toulmin - TriplyDB

VPA response in SMA is suppressed by the fatty acid translocase CD36.

VPA response in SMA is suppressed by the fatty acid translocase CD36.

http://www.wikidata.org/entity/Q34306857

about

Human induced pluripotent stem cells for monogenic disease modelling and therapy Spinal muscular atrophy: from gene discovery to clinical trials iPSC-Based Models to Unravel Key Pathogenetic Processes Underlying Motor Neuron Disease Development Assays for the identification and prioritization of drug candidates for spinal muscular atrophy Stem cell transplantation in neurological diseases: improving effectiveness in animal models Therapeutic opportunities and challenges of induced pluripotent stem cells-derived motor neurons for treatment of amyotrophic lateral sclerosis and motor neuron disease.A Comparative Study of SMN Protein and mRNA in Blood and Fibroblasts in Patients with Spinal Muscular Atrophy and Healthy Controls Splicing factor TRA2B is required for neural progenitor survival.Spinal Muscular Atrophy Biomarker Measurements from Blood Samples in a Clinical Trial of Valproic Acid in Ambulatory Adults.Naturally occurring plant polyphenols as potential therapies for inherited neuromuscular diseases.iPS cells: a game changer for future medicine.Human pluripotent stem cells as tools for neurodegenerative and neurodevelopmental disease modeling and drug discovery.Investigational therapies for the treatment of spinal muscular atrophy.Developing therapies for spinal muscular atrophy.Current status of pluripotent stem cells: moving the first therapies to the clinic.Patient-derived induced pluripotent stem cells in cancer research and precision oncology.A new era of disease modeling and drug discovery using induced pluripotent stem cells.Pluripotent stem cells in neuropsychiatric disorders.Plastin 3 is upregulated in iPSC-derived motoneurons from asymptomatic SMN1-deleted individuals.Valproate Treatment in an ALS Patient Carrying a c.194G>A Spastin Mutation and SMN2 Homozygous Deletion.Moving towards treatments for spinal muscular atrophy: hopes and limits.Overview of Current Drugs and Molecules in Development for Spinal Muscular Atrophy Therapy.

P2860

Q26750393-BAAB8DE1-1B9B-48FC-B92C-023E5C1F5192 Q26824894-9222C82C-83EA-45C4-AE10-5538EC9F75D5 Q26863612-8097ED0A-F833-48BE-BC75-88D7CF61CB1B Q34082155-112EE322-63C1-42F5-A723-A313A48B8B16 Q34391064-9D4A0F52-3AC7-43C3-8C0A-C33687789FFB Q34557892-96832F6A-2580-411A-90EA-80D85C4F51D0 Q36205773-C556004F-0898-4C7B-9727-4041664AE290 Q37374977-B593277D-148E-48FE-B502-6C6AA49146B0 Q37610527-CA3674A2-1763-4F21-81FE-79FA65A51BDA Q38161550-7D58508B-C1B7-42F2-9A04-CD2176BA58AF Q38185513-A87DA793-31BD-4065-A624-6662463259CC Q38428477-16656050-FD20-4C18-A3D0-039180BC9FBC Q38441280-20E092EF-9305-44D4-8B9A-BACB446BB265 Q38546908-67616362-ED55-4031-855D-EA06565434BB Q38590664-CD746747-8580-4770-AF59-C8E5747933E8 Q38786566-6CEF35CC-717E-4F20-83BE-1E588640D0D5 Q38786732-7C428856-1072-422B-AB85-61C201CE18A9 Q39189500-E17AC966-6FAA-476E-B9C6-AC495FDCB8AD Q41119982-FA5F0333-0A0A-451E-B34F-1C4541F13553 Q42100957-B8166EF8-6464-488E-B75B-1286BE5FA331 Q45875383-F474312D-F41A-4E60-BC2A-132E149B54AA Q48144714-7B3D8092-14A8-493F-9693-B552E3DDDE9D

P2860

VPA response in SMA is suppressed by the fatty acid translocase CD36.

http://www.wikidata.org/entity/Q34306857

description

2012 nî lūn-bûn

@nan

2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

VPA response in SMA is suppressed by the fatty acid translocase CD36.

@ast

VPA response in SMA is suppressed by the fatty acid translocase CD36.

@en

VPA response in SMA is suppressed by the fatty acid translocase CD36.

@nl

type

label

VPA response in SMA is suppressed by the fatty acid translocase CD36.

@ast

VPA response in SMA is suppressed by the fatty acid translocase CD36.

@en

VPA response in SMA is suppressed by the fatty acid translocase CD36.

@nl

prefLabel

VPA response in SMA is suppressed by the fatty acid translocase CD36.

@ast

VPA response in SMA is suppressed by the fatty acid translocase CD36.

@en

VPA response in SMA is suppressed by the fatty acid translocase CD36.

@nl

P1433

Q34306857-01606708-B75E-450A-B83C-7DFAD11BAE51

P1476

Q34306857-A88438CB-5872-4353-AD6A-75DDC33EB2BE

P2093

Q34306857-087443A8-B740-4D37-9E0E-9B83ADDC1833

Q34306857-28FB2BB2-AC1D-488B-BD23-ECAA08669CA2

Q34306857-3E3A4A0B-9384-4F1C-8B82-D48D5BF94531

Q34306857-41BB44FC-97E8-4B70-9B89-284D2BFCFE0D

Q34306857-5A92EF3E-F65D-4352-8A56-8429CB9CA3D4

Q34306857-A30F8829-3230-4BC0-9E6D-BF7F21B5817A

Q34306857-AD0ABAAA-38BA-4BCA-BD0A-008E1128EFC0

Q34306857-AD50A429-510C-4315-BCE2-0DB1A17143A7

Q34306857-DBE53C9D-CF8D-4DD6-9306-47F19EC53321

Q34306857-DD7114BD-74AB-4369-B616-68B7FD272C12

P2860

Q34306857-02D4EACA-8E86-48C6-B282-610A166FB385

Q34306857-043729E2-545D-4FCB-838C-63CE70E22A0B

Q34306857-07DD452C-2482-4EB1-B310-AE010EA1F2E1

Q34306857-0A62C642-83BD-4C81-9246-DAA6E268C096

Q34306857-0D2A3F64-5204-4815-A4C4-85D9E5C0581E

Q34306857-0FA4A6EE-7F13-4CE5-85CC-DEAAFA199DD3

Q34306857-12308E95-ECB9-4C34-90F6-A40819174356

Q34306857-1293036B-9E87-4620-AB12-4682916E6106

Q34306857-146B707B-DD79-4F18-B4C1-D2D435F749D7

Q34306857-1B12DF34-55D0-4E9C-991B-FFD11F12C486

P304

Q34306857-BF767DD5-38AF-4000-B741-BEF6888EBC1E

P31

Q34306857-F25EB97A-8563-405A-AD65-0E6600B955CF

P356

Q34306857-77592EFF-3F71-4512-BC13-2A00C5B13E8E

P433

Q34306857-85225F66-021F-4335-BAA7-FB9BCC1B99C0

P478

Q34306857-569A3D35-7947-43BD-A100-19303794934E

P577

Q34306857-C121803D-4E26-406C-8746-8BD696FE7282

P5875

Q34306857-5A6DBCAA-98A9-4DED-BCBC-0AECE12BD755

P698

Q34306857-9B285731-324F-4E71-936D-3F640CDC16A1

P921

Q34306857-0D5722A8-9692-4502-A530-461D52FBB33E

P356

P1433

Human Molecular Genetics

P1476

VPA response in SMA is suppressed by the fatty acid translocase CD36.

@en

P2093

Brunhilde Wirth

http://www.w3.org/2001/XMLSchema#string

Irmgard Hölker

http://www.w3.org/2001/XMLSchema#string

John Dimos

http://www.w3.org/2001/XMLSchema#string

Julia Schreml

http://www.w3.org/2001/XMLSchema#string

Katharina Zimmermann

http://www.w3.org/2001/XMLSchema#string

Ludwig Heesen

http://www.w3.org/2001/XMLSchema#string

Lutz Garbes

http://www.w3.org/2001/XMLSchema#string

Michael Peitz

http://www.w3.org/2001/XMLSchema#string

Michael Walter

http://www.w3.org/2001/XMLSchema#string

Michaela Thoenes

http://www.w3.org/2001/XMLSchema#string

P2860

Evaluation of muscle strength and motor abilities in children with type II and III spinal muscle atrophy treated with valproic acid

SMA CARNIVAL TRIAL PART II: a prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy

SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy

Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages

Induction of pluripotent stem cells from adult human fibroblasts by defined factors

Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy

Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy

The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells

A modified Hammersmith functional motor scale for use in multi-center research on spinal muscular atrophy

LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate

P304

398-407

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/HMG/DDS437

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2012-10-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232281470

http://www.w3.org/2001/XMLSchema#string

P698

23077215

http://www.w3.org/2001/XMLSchema#string

P921